Eurobio Onclogy

News & Blogs

Please note that some articles are available only in their original language to ensure regulatory compliance and preserve the accuracy of the original scientific content and references.

Watch Myriad Genetics’ ESMO 2022 Industry Satellite Symposium
September 19, 2022

we use genetic signatures for chemotherapy decisions in ER+/HER2- premenopausal patients? Dr. Anastasia Constantinidou shares key new data from ESMO Congress 2022 demonstrating how EndoPredict can help guide treatment decisions and avoid overtreatment for premenopausal women with ER+, HER2- early breast cancer.

Retour en haut